Zielone swiatlo dla J&J esketaminy

Nie jestem wrozem ale na tym portlu pisalem o tym rok temu. Jest to nie jest njlepsza wiadomosc dla CLN bo jesli nawet ich forma podawanie jest lepsza niz J&J to wygranie z komercjalna machina J&J bedzie szalenie trudne. Dodatkowo FDA moze wymagac uzycia produktu J&J jako porownawczego. Bedzie to szalenie kosztowne.
FDA Advisory Panel Recommends Approval Of Esketamine For Depression.
The New York Times (2/12, Carey) reports an FDA advisory panel recommended approval of Johnson & Johnson’s esketamine, which has the same active ingredient as ketamine, for the treatment of severe depression. The FDA “has until March 4 to decide whether to approve the drug.”
        Bloomberg News (2/12, Koons, Edney) reports esketamine is “administered via a nasal spray,” and “is being tested in major depressive disorder and suicidal thinking.”
        Business Insider (2/12, Brodwin) reports that if approved, the drug would be “the first new kind of depression medication in 35 years.” Wilson Compton, the deputy director of the National Institute on Drug Abuse who sat on the panel, said, “I was persuaded not only by the two positive trials but even by the partial evidence in the third trial that was at least pointing in the same direction.”
        Also covering the story are CNN (2/12, Nedelman), STAT (2/12, Thielking), MD Magazine (2/12, Gingerich), and MedPage Today (2/12, George).